Correction: Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

Mandalá M, Larkin J, Ascierto PA, *et al.* Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. *J Immunother Cancer* 2021;9:e003188. doi: 10.1136/jitc-2021-003188.

This article has been corrected since it was first published. Author name has been corrected from 'Ivan Marquez' to 'Ivan Marquez-Rodas'.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2021;9:e003188corr1. doi:10.1136/jitc-2021-003188corr1